Endocrine Abstracts

Background: It has been reported that metformin might modify thyroid hormone economy. This farmacological tool appears very useful in patients with differentiated thyroid cancer usually receiving high Levo-tiroxine (L-T4) doses to suppress thyrotropin (TSH). In those patients that after five years of follow-up showed no persistence of disease, it’s useful to abolish the iatrogenic hyperthyroid condition.Objective: To evaluate metformi...

Background: Insulin-resistance phenomenon is a key factor in the pathogenesis of Metabolic Syndrome (MS). Several reports focus on the identification of a role of Insulin to trigger thyrocytes proliferation in vitro. Thyroid IRS-1 mRNA expression increased progressively during goitrogenesis in vivo. In order to individuate the impact of clinical and biochemical markers of MS on the growth-score of non toxic multinodular goiter (MNG) we evaluated a population of 6...

Background: The last American Thyroid Association guidelines (ATA-2015) defined the risk of structural recurrence in patients with DTC cured after initial treatment and according to the initial histology. However, these data resulted from several studies including different patients with different kinds of treatment. We retrospectively evaluated a large population of patients with DTC, treated and followed in a tertiary referral center, with the aim to characterize the rate of...

Introduction: Hand-foot syndrome (HFS), or palmo-plantar erythrodysplasia, is an adverse event related to lenvatinib therapy. In the clinical trial (SELECT study) HFS was reported in 32% of patients, but only 3% was grade ≥3. In real-life studies the frequency was variable: between 8 and 55%.Patients: We collected clinical and pathological data about 165 patients with thyroid cancer treated with lenvatinib, followed up between 2012 and 2022 at the ...